From a price-performance perspective, BMY has fetched slightly better returns than AMGN in the past six months. Shares of ...

After a weak first half, the drug and biotech sector has recovered in the past 2-3 months, with most large drugmakers signing drug pricing agreements with the Trump administration. After a cautious ...

Both Novo Nordisk NVO and Amgen AMGN are large-cap, innovation-driven healthcare leaders with global scale, strong balance ...

US companies Amgen, Bristol Myers Squibb, Gilead Sciences, and Merck/MSD have signed up to reduce the prices of medicines for ...

A. Your doctor was correct that depression and suicidal thoughts do not appear in the official prescribing information for evolocumab (Repatha) or a similar drug, alirocumab (Praluent). Both are ...

Q. I developed severe depression while taking Repatha, the injectable cholesterol lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...

At Ford Field on Thursday, Amon-Ra St. Brown and the Detroit Lions (7-5) face Javonte Williams and the Dallas Cowboys (6-5-1) in a matchup featuring two of the brightest stars in the NFL, beginning at ...

Pluribus Episode 4, “Please, Carol,” took viewers and characters on yet another a wild ride. But this time, a hospital, needles, drugs, and lots of tears were involved. Pluribus Episode 4 spoilers ...

Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...

(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...

Nov 8 (Reuters) - Adding Amgen's (AMGN.O), opens new tab cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack ...

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha ® -treated and placebo-treated patients, respectively. The most common ...